HR+/HER2-乳腺癌内分泌治疗的研究进展

The trend of endocrine therapeutic approach in HR+/HER2-breast cancer

乳腺癌在当今社会女性癌症类型中具有高发生率及高死亡率特征。根据激素受体(HR)和人表皮因子生长受体-2(HER2)表达的不同,在分子分型上将乳腺癌分为五型。其中占比约70%的HR+/HER2-(包含Luminal A型、Luminal B HER2-型)类型,为乳腺癌治疗的重中之重。除手术及非手术放化疗等传统疗法外,内分泌治疗在这一类型患者的治疗方案中有着举足轻重的地位。20世纪以来,多种内分泌治疗方法应运而生,为无数患者带来了曙光。文章从雌激素受体拮抗剂、芳香化酶抑制剂以及内分泌联合靶向等方面对激素受体阳性的乳腺癌患者内分泌治疗的发展历史以及最新的临床研究结果进行综述。

Breast cancer(BC)is one of the top types of the malignant tumors in today's society,characterized by high morbidity and mortality.In terms of molecular typing,breast cancer is categorized into five subtypes according to the expression level of hormone receptor(HR)and human epidermal growth factor receptor type2(HER2).Patients with HR+/HER2-(includingLuminal A type,Luminal B HER2-type)breast cancer subtype account for nearly 70%of the total cases.Except conventional therapies,including surgery and non-surgical chemoradiotherapy,endocrine therapeutic strategy is pivotally emphasized.A series of endocrine therapy pharmaceutical studies have been emerged consecutively since the beginning of 20 th century,and bring dawn to millions of patients to live longer and more healthily.Here,we aimed to review the progress of endocrine therapy in hormone receptor-positive breast cancer patients and the latest clinical research results from the aspects of selective estrogen receptor modulators(SERMs),aromatase inhibitors(AI),and endocrine therapy combined with targeted therapy.